Answers are grounded in this paper and cite their sources.
Funding sources: none. Conflicts of interest: S.W. has a speaking arrangement with Novartis, Bayer‐Onyx, Pfizer and Medivation, Inc. M.E.L. has a speaking, consultant or advisory role with Advancell, Amgen, AstraZeneca, Augmentium, Aveo, Bayer, Berg Pharma, Biopharm Communications, Boehringer Ingelheim, Brickell Biotech, Bristol‐Myers Squibb, Clinical Assistance Programs, Clinical Care Options, EMD Serono, Envision Communications, Foamix, Galderma, Genentech, GlaxoSmithKline, Helsinn, Institute for Medical Education and Research, Lindi Skin, Medscape, Medtrend International, Merck, NeRRe Therapeutics, Novartis, Novocure, Oncology Specialty Group, OSI Pharmaceuticals, Physicians Education Resource, Pierre Fabre, Pfizer, Reata Pharmaceuticals, Roche, Sandoz, Sanofi Aventis and Threshold Pharmaceuticals. Dear Editor, Taxanes are an established and powerful class of cytotoxic chemotherapeutic agents that exhibit a wide spectrum of activity against solid tumours including breast, ovarian, lung, head and neck, stomach, pancreatic and prostate cancers.1,2,3 This antitubulin/antimitotic class of drugs includes paclitaxel, docetaxel and the newer nanoparticle albumin‐bound (nab)‐paclitaxel.4 The range of dermatological adverse events (AEs) is broad and includes nail changes such as hyperpigmentation, discolouration, splinter haemorrhages, subungual haematomas and Beau lines.5 Periungual erythema, oedema, exudation and granulation tissue are other nail‐related AEs that could potentially result in partial/total onycholysis and subungual abscesses, and represent the more common and often dose‐limiting changes.6
No takes yet. Share an insight, caveat, or question.
Capriotti et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: